TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

By Wang Jiayu  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 531-537

Springer Publishing Company

Access to resources Recommend Favorite

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

By Bertucci François  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 363-373

Springer Publishing Company

Access to resources Recommend Favorite

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer

By Arriagada Rodrigo   Spielmann Marc   Koscielny Serge   Le Chevalier Thierry   Delozier Thierry   Rémé-Saumon Monique   Ducourtieux Muriel   Tursz Thomas   Hill Catherine  

Acta Oncologica, Vol. 44, Iss. 5, 2005-07 ,pp. : 458-466

Informa Healthcare

Access to resources Recommend Favorite

Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates

By Kanjer Ksenija  

Pathology & Oncology Research, Vol. 19, Iss. 3, 2013-07 ,pp. : 577-588

Springer Publishing Company

Access to resources Recommend Favorite

Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome

By Ozmen V.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 147-157

Springer Publishing Company

Access to resources Recommend Favorite